« Zurück
Startseite /
Mouse LY75 / CD205 Protein, His Tag (MALS verified)

Mouse LY75 / CD205 Protein, His Tag (MALS verified)

ArtNr	LY5-M52H5-1mg
Hersteller	ACROBiosystems
Menge	250 ug x 4
Quantity options	100 ug 250 ug x 4
Kategorie	Peptides & Proteins Recombinant Proteins
Typ	Proteins Recombinant
Format	Solid
Specific against	Mouse (Murine, Mus musculus)
Host	HEK293
Konjugat/Tag	Unconjugated, HIS
Purity	90%
Citations	(1) Eugenio Gaudio, et al. Haematologica. 2020. 105(11):2584-2591. (2) Sadia Mehdi, et al. Int J Mol Sci. 2020. 21(14):4992. (3) Sheikh Tasnim Jahan, et al. Int J Nanomedicine. 2015. 10:7371-84.
NCBI	NP_038853.2
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Category	Protein
Manufacturer - Conjugate / Tag	C-10xHis, Unconjugated
Shipping Temperature	RT
Storage Conditions	-20°C
Molecular Weight	190.0 kDa
Manufacturer - Species	Mouse
Manufacturer - Format	Powder
Description	lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
Background	lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
Molecule	LY75
Exp Region	Ser 28 - Asp 1667
Characteristics	This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 190.0 kDa. The protein migrates as 230-260 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin	1.0 EU per μg
Buffer	PBS, pH7.4
Stability	● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant	trehalose

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

LY5-M52H5-1mg-datasheet.pdf

LY5-M52H5-1mg-safety-datasheet.pdf